Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
2003-03-20
2010-02-02
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S093480, C424S093200, C424S258100, C424S234100, C424S184100, C435S069300, C435S069100, C435S069700
Reexamination Certificate
active
07655241
ABSTRACT:
The present invention concerns the use of methods and compositions to prophylactically or therapeutically vaccinate a subject against a pathogen or disease. Embodiments of the invention include the production of an attenuated bacterium from the family Enterobacteriaceae with a non-functional lipoprotein for use as a vaccine or as a vaccine vector for delivering antigens to a subject to be vaccinated. In certain embodiments, a bacterium of the Enterobacteriaceae family lacking a wild type LP, for exampleSalmonella typhimuriumlacking a wild type LP, may be produced and used as a vaccine or vaccine vector.
REFERENCES:
patent: 4624926 (1986-11-01), Inouye et al.
patent: 5348867 (1994-09-01), Georgiou et al.
patent: 5554372 (1996-09-01), Hunter
patent: 6605709 (2003-08-01), Breton
patent: 6610836 (2003-08-01), Breton et al.
patent: 2003/0131376 (2003-07-01), Okubara et al.
patent: 0300459 (1989-01-01), None
Zwiebel et al. J. Bacteriol. 145: 654-656, 1981.
Gupta et al. J. Biol. Chem. 268: 16551-16556, 1993.
Nakamura et al. EMBO J. 1: 771-775, 1982.
Zhang et al. J. Immunol. 159: 4868-4878, 1997.
Zhang et al. Infect. Immun. 66: 5196-5201, 1998.
Kanamori et al. Gene 66: 295-300, 1988.
Beck et al. J. Bacteriol. 181: 7285-7290, 1999.
Sambrook et al. Molecular Cloning. A Laboratory Manual. Second Edition, Cold Spring Harbor, pp. 17.1-17.44, 1989.
Henriksen et al. APMIS 97: 559-568, 1989.
Nakamura et al. PNAS 77: 1369-1373, 1980.
Brett et al.,J. Immunol., “Comparison of antigen presentation of influenza a nucleoprotien expressed in attenuated aroA-Salmonella typhimuriumwith that of live virus,”150:2869-2884, 1993.
Ching and Inouye, “Evolution of the lipoprotein gene in the enterobacteriaceae—cloning and DNA sequence of the Ipp gene fromProteus mirabilis,” J. Mol. Biol., 185:501-507, 1985.
Coynault et al.,Mol. Microbiol., “Virulence and vaccine potential ofSalmonella typhimuriummutants deficient in the expression of the RpoS ([sigma]s) regulon,” 22:149-160, 1996.
Fouts et al., “Construction and immunogenicity ofSalmonella typhimuriumvaccine vector that express HIV-1 gp120,”Vaccine, 13:1697-1705, 1995.
Huang et al., “Comparison of the lipoprotein gene among the enterobacteriaceae,”J. Biol. Chem., 258:8139-8145, 1983.
Nakamura and Inouye, “DNA Sequence of the gene for the outer membrane lipoprotein ofE. coli: an extremely AT-rich promoter,”Cell, 18:1109-1117, 1979.
Noriega et al., “Engineered ΔaguaB-A ΔvirG Shigella flexneri 2a strain CVD 1205: construction, safety, immunogenicity, and potential effecacy as a mucosal vaccine,”Infect. Immun., 64:3055-3061, 1996.
Sizemore et al, “Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization,”Science, 270:299-302, 1995.
Yamagata et al., “Comparison of the lipoprotein gene among the enterobacteriaceae,”J. Biol. Chem., 256:2194-2198, 1981.
Chopra Ashok
Klimpel Gary R.
Niesel David W.
Sha Jian
Devi S.
Fulbright & Jaworski L.L.P.
The Board of Regents of the University of Texas System
LandOfFree
Methods and compositions for vaccination against or... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for vaccination against or..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for vaccination against or... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4194491